← Research library

Imunofan alongside multimodal breast cancer treatment — RU2270693C2

Patent disclosure · 2006

What the patent describes
Two patients aged 39 and 46 with stage IIB and IIIB breast cancer, respectively. Both received cancer care plus three five-day IM Imunofan courses. The Russian description and claim specify 0.005%, 1 mL daily. The abstract gives 0.05%, a conflicting concentration.
Reported evidence
The patent describes two breast cancer cases in which T-cell measures rose during combined treatment. Both were reported free of recognized recurrence or metastasis at the 12-month examination.

Case 2, CD3 and CD4 cells · CD3-positive cells went from 520 to 1,700 cells/mm³ and CD4-positive cells from 290 to 590 cells/mm³ by the end of multimodal treatment.

Reported patent results

Reported findings

The patent describes two breast cancer cases in which T-cell measures rose during combined treatment. Both were reported free of recognized recurrence or metastasis at the 12-month examination.

Two patients aged 39 and 46 with stage IIB and IIIB breast cancer, respectively. Both received cancer care plus three five-day IM Imunofan courses. The Russian description and claim specify 0.005%, 1 mL daily. The abstract gives 0.05%, a conflicting concentration.

Population or model Two patients aged 39 and 46 with stage IIB and IIIB breast cancer, respectively. Both received cancer care plus three five-day IM Imunofan courses. The Russian description and claim specify 0.005%, 1 mL daily. The abstract gives 0.05%, a conflicting concentration.

Results · Russian grant, claims and Examples 1–2.
MeasureResultComparison, timing and statistics
Case 2, CD3 and CD4 cellsCD3-positive cells went from 520 to 1,700 cells/mm³ and CD4-positive cells from 290 to 590 cells/mm³ by the end of multimodal treatment.
Case follow-upThe patent reports no recurrence or metastasis detected at 12 months in either illustrative case.

These two examples supply no comparator or estimate of attributable benefit. Whether either case was part of the Samara dissertation cohort is unresolved.

Source for these results ↗ · Reviewed 2026-11-14

Patent claims and provenance

Use. The Russian claim describes three five-day courses of 1 mL of 0.005% Imunofan intramuscularly, after radiation, after surgery and between chemotherapy cycles two and three.

Two uncontrolled cases received radiotherapy, surgery and chemotherapy. A related 174-patient Samara author abstract describes the same regimen and shares an investigator. The case histories may be part of that program.

Publication
RU2270693C2 ↗ · 2006-02-27
Earliest priority / filing
2004-02-24 / 2004-02-24
Original applicant / assignee
Samara State Medical University
Indexed status
IP Right Cessation · checked 2026-11-14
Patent family
35844500 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Способ лечения рака молочной железы

Inventors: S. V. Kozlov; T. G. Zolotareva.

RU2270693C2 · RU2004105372A

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Two uncontrolled cases received radiotherapy, surgery and chemotherapy. A related 174-patient Samara author abstract describes the same regimen and shares an investigator. The case histories may be part of that program.
  • These two examples supply no comparator or estimate of attributable benefit. Whether either case was part of the Samara dissertation cohort is unresolved.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Related publications may describe some of the same participants or experiments.

Source details

Patent publication · Original patent text and indexed metadata

Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Sources checked

Citation

Published

Patent / reported experimentsFull text available

S. V. Kozlov, T. G. Zolotareva. Imunofan alongside multimodal breast cancer treatment — RU2270693C2 RU2270693C2 · patent family 35844500

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards